DiscoverThe Readout Loud
The Readout Loud
Claim Ownership

The Readout Loud

Author: STAT

Subscribed: 764Played: 52,128
Share

Description

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

427 Episodes
Reverse
On this week’s episode of "The Readout LOUD": The FDA is once again searching for a new leader, a closely tracked lung cancer drug suffers an FDA rejection, and China’s largest drugmakers ranked.  We invite you to listen to this pre-Thanksgiving episode of your favorite biotech podcast, where our attention turns to D.C. The Trump administration withdrew the nomination of Heidi Overton to become the next FDA commissioner hours before a pivotal Senate committee vote. STAT’s D.C. correspondent Margaret Manto joins us to explain why Overton was tossed and who might be next in line to run the FDA.  We’ll also chatter away about this week’s news, including the FDA’s rejection of a lung cancer drug from the U.S.-based biotech Summit Therapeutics and the Chinese drug maker Akeso. And speaking of China, STAT just launched a new index ranking China’s largest drugmakers. We’ll discuss how the list was made and why tracking Chinese biotech has become so important.
On this week’s episode of "The Readout LOUD": the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest companies in the sector.  For years, it was widely believed that a deeper understanding of genetics was going to speed the development of newer and better medicines for patients with heart disease. But then came this year’s American Heart Association meeting, which was dominated by presentations of clinical trials that showed no benefit whatsoever for two drugs long thought to be genetically validated.  Joining us to help sort out this cardiovascular conundrum and what it might portend for the future of drug research is our colleague and senior medical writer Matthew Herper. We also chat about drug safety concerns weighing on Vertex Pharmaceuticals and Novartis, and Alnylam’s stock price tumbling on growth concerns.
How will the midterm results affect drug pricing policy? What is the fate of the Food and Drug Administration? And why are women traveling to fertility clinics abroad? On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on our Washington correspondent Daniel Payne to chat about the massive midterm victory for Democrats and what it means for health and medicine. We also bring on our colleague Megan Molteni to discuss her investigation into a network of clinics that have advertised fertility success with a questionable and expensive genetic procedure.
What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology? On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on our colleague Andrew Joseph to discuss the latest cancer data presented at the annual meeting of the European Society for Medical Oncology. We also make an announcement about the podcast.
Helen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient reporting on the flu, polio, Ebola and the Covid-19 pandemic. This week’s episode of “The Readout LOUD” is dedicated to Helen, who died last week due to complications of cancer. We speak with her colleagues at STAT, family and public health leaders about her work and her legacy.
loading
Comments